Related references
Note: Only part of the references are listed.Long-Term Safety and Efficacy of Triple Combination Ezetimibe/Simvastatin Plus Extended-Release Niacin in Patients With Hyperlipidemia
Sergio Fazio et al.
AMERICAN JOURNAL OF CARDIOLOGY (2010)
Differing effect of statins on insulin sensitivity in non-diabetics: A systematic review and meta-analysis
William L. Baker et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2010)
The relative importance of modifiable potential risk factors of type 2 diabetes: a meta-analysis of two cohorts
Maarit A. Laaksonen et al.
EUROPEAN JOURNAL OF EPIDEMIOLOGY (2010)
The Effect of Body Mass Index on Fasting Blood Glucose and Development of Diabetes Mellitus After Initiation of Extended-Release Niacin
Ardelle Libby et al.
METABOLIC SYNDROME AND RELATED DISORDERS (2010)
Demographic Differences and Trends of Vitamin D Insufficiency in the US Population, 1988-2004
Adit A. Ginde et al.
ARCHIVES OF INTERNAL MEDICINE (2009)
Differential metabolic effects of pravastatin and simvastatin in hypercholesterolemic patients
Kwang Kon Koh et al.
ATHEROSCLEROSIS (2009)
Statin Therapy and Risk of Developing Type 2 Diabetes: A Meta-Analysis
Swapnil N. Rajpathak et al.
DIABETES CARE (2009)
Statin therapy, muscle function and vitamin D
M. R. Goldstein et al.
QJM-AN INTERNATIONAL JOURNAL OF MEDICINE (2009)
Low serum 25 (OH) vitamin D levels (<32 ng/mL) are associated with reversible myositis-myalgia in statin-treated patients
Waqas Ahmed et al.
TRANSLATIONAL RESEARCH (2009)
Colesevelam improves glycemic control and lipid management in inadequately controlled type 2 diabetes mellitus
Konstantinos Tziomalos et al.
NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM (2009)
Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study)
Christie M. Ballantyne et al.
AMERICAN JOURNAL OF CARDIOLOGY (2008)
The effect of statins on the development of new-onset type 2 diabetes: a meta-analysis of randomized controlled trials
Craig I. Coleman et al.
CURRENT MEDICAL RESEARCH AND OPINION (2008)
Simvastatin improves flow-mediated dilation but reduces adiponectin levels and insulin sensitivity in hypercholesterolemic patients
Kwang Kon Koh et al.
DIABETES CARE (2008)
Role of vitamin D in the pathogenesis of type 2 diabetes mellitus
X. Palomer et al.
DIABETES OBESITY & METABOLISM (2008)
The HMG-CoA reductase inhibitor rosuvastatin and the angiotensin receptor antagonist candesartan attenuate atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes via effects on advanced glycation, oxidative stress and inflammation
A. C. Calkin et al.
DIABETOLOGIA (2008)
Baseline triglyceride levels and insulin sensitivity are major determinants of the increase of LDL particle size and buoyancy induced by rosuvastatin treatment in patients with primary hyperlipidemia
Michael S. Kostapanos et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2008)
Vascular risk factors in South Asians
Konstantinos Tziomalos et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2008)
Effects of niacin on glucose control in patients with dyslipidemia
Ronald B. Goldberg et al.
MAYO CLINIC PROCEEDINGS (2008)
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Paul M. Ridker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Rosuvastatin in older patients with systolic heart failure
John Kjekshus et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
European guidelines on cardiovascular disease prevention in clinical practice: executive summary
Ian Graham et al.
EUROPEAN HEART JOURNAL (2007)
Impact of new-onset diabetes mellitus on cardiac outcomes in the Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial population
Tonje A. Aksnes et al.
HYPERTENSION (2007)
Niacin in cardiovascular prevention: mechanisms, efficacy, and safety
John R. Guyton
CURRENT OPINION IN LIPIDOLOGY (2007)
Impact of the population at risk of diabetes on projections of diabetes burden in the United States: an epidemic on the way
A. G. Mainous et al.
DIABETOLOGIA (2007)
Atorvastatin decreases serum levels of advanced glycation end products (AGEs) in patients with type 2 diabetes
Y. Jinnouchi et al.
CLINICAL AND EXPERIMENTAL MEDICINE (2006)
Suppression of rage as a basis of simvastatin-dependent plaque stabilization in type 2 diabetes
Chiara Cuccurullo et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2006)
Epidemic obesity and type 2 diabetes in Asia
Kun-Ho Yoon et al.
LANCET (2006)
Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial
Sverre E. Kjeldsen et al.
JOURNAL OF HYPERTENSION (2006)
Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes - The treating to new targets (TNT) study
James Shepherd et al.
DIABETES CARE (2006)
AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update
Sidney C. Smith et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2006)
Evaluation of efficacy and safety of fixed dose lovastatin and niacinER combination in Asian Indian dyslipidemic patients: a multicentric study
Manoj Sharma et al.
VASCULAR HEALTH AND RISK MANAGEMENT (2006)
Preventing type 2 diabetes in high risk patients: An overview of lifestyle and pharmacological measures
EN Liberopoulos et al.
CURRENT DRUG TARGETS (2006)
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study):: randomised controlled trial
A Keech et al.
LANCET (2005)
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins
C Baigent et al.
LANCET (2005)
Diabetic vascular complications: Pathophysiology, biochemical basis and potential therapeutic strategy
S Yamagishi et al.
CURRENT PHARMACEUTICAL DESIGN (2005)
Ethnic differences in mortality, end-stage complications, and quality of care among diabetic patients - A review
LC Lanting et al.
DIABETES CARE (2005)
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines
SM Grundy et al.
CIRCULATION (2004)
Serum 25-hydroxyvitamin D, diabetes, and ethnicity in the Third National Health and Nutrition Examination Survey
R Scragg et al.
DIABETES CARE (2004)
The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study
VG Athyros et al.
JOURNAL OF CLINICAL PATHOLOGY (2004)
Reduced incidence of new-onset diabetes mellitus after renal transplantation with 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins)
GVR Prasad et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2004)
Adverse prognostic significance of new diabetes in treated hypertensive subjects
P Verdecchia et al.
HYPERTENSION (2004)
Early benefit from structured care with atorvastatin in patients with coronary heart disease and diabetes mellitus - A subgroup analysis of the GREek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study
VG Athyros et al.
ANGIOLOGY (2003)
Effect of fluvastatin on cardiac outcomes in renal transplant recipients:: a multicentre, randomised, placebo-controlled trial
H Holdaas et al.
LANCET (2003)
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA):: a multicentre randomised controlled trial
PS Sever et al.
LANCET (2003)
Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial
J Shepherd et al.
LANCET (2002)
Diabetes mellitus: perspective from the Asia-Pacific region
CS Cockram
DIABETES RESEARCH AND CLINICAL PRACTICE (2000)
Share Paper
